Marksans Pharma Limited has informed the Exchange regarding a press release dated May 19, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for the product Sennosides 7.5 mg Tablets".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma's wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for Sennosides 7.5 mg Tablets, a gastrointestinal product used as a laxative. Sennosides is used in the treatment of constipation and bowel preparation before procedures. The approval enables Relonchem to market this product in the UK. Marksans Pharma, headquartered in Mumbai, manufactures and markets generic pharmaceutical formulations globally with facilities in India, USA, and UK approved by major regulatory bodies including USFDA, UKMHRA, and Australian TGA.
This is a routine regulatory approval for a generic product through the company's UK subsidiary, adding to its gastroenterology portfolio. It may contribute modestly to UK revenues but is unlikely to cause significant movement in the stock price on its own.